Vitrafy enters U.S. Cell & Gene Therapy Market
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Vitrafy Life Sciences Ltd. has announced an agreement with Charter Medical to enter the U.S. cell and gene therapy market by deploying its cryopreservation ecosystem at Charter Medical's Innovation Hub. This agreement marks Vitrafy's first venture into the North American market and aims to support cryopreservation and freeze curve optimisation for Charter Medical's customers. The deployment will occur over an initial six-month term, with no revenue expected during this period. The partnership is expected to enhance the performance of Charter Medical's products and could lead to further commercial opportunities in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vitrafy Life Sciences Ltd. on 6ix
Earlier from Vitrafy Life Sciences
- FY26 Full Year Results Presentation
- FY26 Appendix 4E and Annual Report
- FY26 Corporate Governance Statement
- FY26 Appendix 4G
- Vitrafy FY26 Investor Briefing
Later from Vitrafy Life Sciences
- S&P DJI Announces September 2026 Quarterly Rebalance
- Vitrafy enters partnership with Versiti Blood Health
- Change to CEO Remuneration and Employment Terms
- Investor Roadshow Presentation
- 2026 Notice of Annual General Meeting
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences